Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01030562 · ClinicalTrials.gov registry record
Immunogenicity of Off-Schedule Dosing of HPV Vaccine
A clinical trial of Papilloma Viral Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 1,321
- Enrollment target
- 7
- Study locations
NCT01030562 is a study of Papilloma Viral Infection that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 1,321 participants. The trial reports 7 study locations across 7 states.
The verdict
NCT01030562, a study of Papilloma Viral Infection, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 1,321 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to gain a better understanding of the body's response to a human papillomavirus (HPV) (sexually transmitted disease), vaccine and booster shot. The study will also determine factors related to adolescents not following vaccination schedules. The HPV vaccine requires 3 doses (shots). Girls sometimes receive the 3 shots at the recommended time and sometimes girls receive the shots at non-recommended times. This study will evaluate if getting the shots at non-recommended times affects the level of protection provided by the vaccine. Participants will include about 1400 girls 9-17 years old receiving a third dose of HPV vaccine from their primary care clinician. The parent/legal guardian of each subject may answer a questionnaire related to the vaccine schedule. Study procedures include: medical history, questionnaires and blood draws. Participants will be involved in the study for about 6 months from time of enrollment.
Conditions Studied
Study Locations (7)
Georgia
- Kaiser Permanente Crescent Medical Center - Pediatrics/Adolescent Medicine - Tucker
Maryland
- University of Maryland School of Medicine - Center for Vaccine Development - Baltimore - Baltimore
Missouri
- Children's Mercy Hospital and Clinics - Infectious Diseases - Kansas City
Ohio
- Cincinnati Children?s Hospital Medical Center - Adolescent Medicine - Cincinnati
Pennsylvania
- Primary Physicians Research Inc. - Pittsburgh - Pittsburgh
Tennessee
- Monroe Carell Jr. Children's Hospital at Vanderbilt - Adolescent Medicine - Nashville
Washington
- Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,321 participants |
| Start Date | 2010-06-02 |
| Est. Completion | 2014-03-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01030562
The ClinicalTrials.gov registry entry for NCT01030562 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,321 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Papilloma Viral Infection appearing as the primary indexed condition, and to 0 interventions.
NCT01030562 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Georgia, Maryland, Missouri.
Frequently Asked Questions
What is clinical trial NCT01030562 about?
NCT01030562 is a clinical study titled "Immunogenicity of Off-Schedule Dosing of HPV Vaccine". The purpose of this study is to gain a better understanding of the body's response to a human papillomavirus (HPV) (sexually transmitted disease), vaccine and booster shot. The study will also determine factors related to adolescents not following vaccination schedules. The HPV vaccine requires 3 do...
What is the current status of trial NCT01030562?
This trial is currently completed. The enrollment target is 1,321 participants. The study started on 2010-06-02. Estimated completion is 2014-03-05.
What conditions does trial NCT01030562 study?
This clinical trial studies the following conditions: Papilloma Viral Infection.
Who is sponsoring clinical trial NCT01030562?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01030562 being conducted?
This trial has 7 study locations across Georgia, Maryland, Missouri, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papilloma Viral Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.